Drug sponsors and their contract service providers are using more sophisticated, integrated and coordinated relationship structures to deliver greater speed and efficiency, a trend that is expected to accelerate, according to a panel of leaders from the research-based drug industry recently convened by the USA’s Tufts Center for the Study of Drug Development.
"Sponsors are adopting relationships with their technical and support service providers much the same way they have established strategic, integrated alliances with contract clinical research service providers," said Ken Getz, assistant professor at Tufts CSDD, adding: "These services, once considered an afterthought, are increasingly viewed as integral to driving better project planning and higher levels of performance and efficiency."
The adoption of these relationships, he said, is due in part to the growing numbers of increasingly complex, global clinical trials that require drug development sponsors to manage ever-more diverse combinations of contract technical and support services, such as clinical supplies, testing, and cardiac safety assessments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze